Amgen, J&J feud over hot anemia drug

Article Abstract:

Amgen Inc and Johnson and Johnson are holding a secret arbitration in Chicago over marketing rights to the successor of the anemia drug erythropoietin, or EPO. EPO was invented by Amgen in 1985 and now has $3 bil in worldwide sales yearly. An early agreement gives Amgen rights to market EPO in the US for kidney-dialysis treatment, and gives J and J most other rights to EPO. Amgen modified the original EPO molecule to create novel erythropoiesis stimulating protein (NESP), which can be given in less frequent doses than EPO. If NESP is judged to be an improvement of EPO, J and J will have rights to the new drug. If NESP is judged to be biologically distinct, Amgen will have full marketing rights.

Comment:

Holds a secret arbitration with Amgen over marketing rights to the successor of erythropoietin

Company Planning/Goals, Patents & copyrights, Licensing/Sales Agreements, Hematinic Preparations, Johnson & Johnson, Hematinics, Article

---

Amgen gets shot in the arm from arbitrators' ruling; award of sole rights to anemia drug sends company's shares soaring

Article Abstract:

Amgen Inc. needs some new drugs, fewer legal battles to fight, and a shot in the arm. A Chicago arbitrator ruled for the shot in the arm: Amgen has the legal right to be the sole marketer of a new anemia drug called novel erythropoesisis stimulating protein or NESP, which boosts production of red blood cells like its predecessor EPO only in fewer doses. NESP is still in clinical trials, but expected to gain approval for market by 2001 or sooner. Amgen currently shares marketing of EPO with Johnson & Johnson in a co-marketing agreement that dates back to 1985.

Comment:

Co. can market new drug for anemia without sharing sales with J&J

Marketing procedures, New Products/Services, Pharmaceutical preparations, Legal/Government Regulation, Care and treatment, Drugs, Pharmaceutical industry, Marketing, Anemia, Abstract, AMGN

---

Similar abstracts:

• Abstracts: Home builders begin to see the advantages of consolidation. 'South Park' creators plan cartoon series for the Web
• Abstracts: Bankruptcy judge approves $25 milion loan for Livent. Livent gets $5 million from board; troubled company seeks more funds
• Abstracts: Celadon prospers as its trucks cruise the NAFTA trail. Sara Lee Corp. recalls meat, plans charge. Lilly's net jumped 24% in 4th quarter as new drugs offset Prozac slowdown
• Abstracts: Computer age gains respect of economists. A parent's view of the World Wide Web as it reaches adolescence
• Abstracts: A new Leo Burnett acquisition will bestow on the agency company that T-word cachet. Ammirati Puris Lintas stakes its claim to cyberspace with a new unit, APL Digital

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.